What is ATB Therapeutics?
Founded in 2017, ATB Therapeutics is a biotechnology firm focused on developing a novel class of immunotherapeutics. The company's proprietary technology is engineered to achieve a high efficacy and safety profile, targeting difficult-to-treat hematological and solid cancers. ATB Therapeutics is currently entering its preclinical stage, aiming to build a robust pipeline of therapeutic assets. The company's strategic focus on unmet needs in oncology positions it within a critical segment of the pharmaceutical industry.
How much funding has ATB Therapeutics raised?
ATB Therapeutics has raised a total of $57.2M across 1 funding round:
Series A
$57.2M
Series A (2024): $57.2M with participation from EQT Life Sciences and MRL Ventures Fund
Key Investors in ATB Therapeutics
EQT Life Sciences
EQT Life Sciences is a prominent investment firm specializing in the life sciences sector, providing capital and strategic support to innovative companies.
MRL Ventures Fund
MRL Ventures Fund (MRLV) is a therapeutics-focused corporate venture group that partners with visionary founders to invest in early-stage, preclinical therapeutics companies globally. The fund provides capital, strategic guidance, and access to MSD's expertise to accelerate the development of breakthrough therapeutics aimed at transforming patient care.
What's next for ATB Therapeutics?
With this substantial enterprise-level funding, ATB Therapeutics is poised to accelerate its preclinical development and expand its pipeline of innovative cancer therapies. The strategic investment will likely fuel further research and development, enabling the company to progress its lead assets towards clinical trials. This capital injection signifies strong investor confidence in ATB Therapeutics' technology and its potential to address significant challenges in cancer treatment, paving the way for future growth and market entry.
See full ATB Therapeutics company page
